<DOC>
	<DOCNO>NCT01794182</DOCNO>
	<brief_summary>This randomize , multi-center , prospective , double blind study . The primary objective demonstrate efficacy RP-1127 compare placebo subject severe anterior circulation ischemic stroke likely develop malignant edema . This objective address compare proportion RP-1127 treat patient placebo treat patient Day 90 modify Rankin Scale ( mRS ) ≤ 4 without decompressive craniectomy ( DC ) .</brief_summary>
	<brief_title>Glyburide Advantage Malignant Edema Stroke - Remedy Pharmaceuticals</brief_title>
	<detailed_description>The study population consist subject clinical diagnosis acute severe anterior circulation ischemic stroke , baseline diffusion weight image ( DWI ) lesion 82 300 cm3 , age 18-80 year , time symptom onset start study infusion ≤10 hour . The study enroll patient receive IV rtPA receive IV rtPA within 4.5 hour stroke . Enrollment randomize control site , age ≤60 ( yes/no ) , IV rtPA treatment baseline ( yes/no ) . Subjects randomize equally RP-1127 placebo .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Anthrax</mesh_term>
	<mesh_term>Gas Gangrene</mesh_term>
	<mesh_term>Glyburide</mesh_term>
	<criteria>A clinical diagnosis acute ischemic stroke MCA territory ( PCA and/or ACA territory involvement addition primary MCA territory stroke acceptable ) . Prior stroke , disability , significant disability despite symptom ( able carry usual duty activity ) . A baseline DWI lesion 82 300 cm3 MRI . Patients treat IV rtPA meet establish criterion IV rtPA administration 03 34.5 hr time period time rtPA administration ( rtPA administer 34.5 hr time window , NIHSS must ≤ 25 time rtPA administration ) . The time start infusion Study Drug must ≤ 10 hour time symptom onset , know , time last see well [ term `` time last known neurologic baseline '' ( TLK @ B ) ] . Age ≥18 year ≤80 year . Provision write informed consent legally authorize representative accord institutional guideline national regulation . Commitment decompressive craniectomy ( DC ) prior enrollment , follow enrollment prior start Study Drug . Treatment intraarterial ( IA ) rtPA mechanical mean clot disruption . Patients unable tolerate MRI scanning , e.g . pacemaker automatic defibrillator . Evidence ( clinical imaging ) concurrent infarction contralateral hemisphere deem investigator sufficiently serious affect functional outcome . Clinical sign herniation , e.g . one two dilate , fix pupil ; unconsciousness ( i.e. , ≥ 2 item 1a NIHSS ) ; and/or loss brain stem reflex attributable edema herniation accord investigator 's judgment . Hemorrhage ( small petechial hemorrhage ) CT/MRI , CT/MRI evidence anteroseptal/pineal shift great ≥2 mm prior enrollment due cerebral edema . Severe renal disorder patient 's history ( e.g . dialysis ) eGFR &lt; 30 mL/min/1.73 m2 . Severe liver disease ALT &gt; 3 time normal , bilirubin &gt; 2 time normal . Blood glucose &lt; 55 mg/dL enrollment immediately prior administration Study Drug , clinically significant history hypoglycemia . Acute ST elevation myocardial infarction , and/or acute decompensated HF , and/or QTc &gt; 520 m , and/or know history cardiac arrest ( PEA , VT , VF , asystole ) , and/or admission ACS , MI , coronary intervention ( PCI coronary artery surgery ) within past 3 month . Known sulfonylurea treatment within 7 day . Sulfonylureas include glyburide /glibenclamide ( Diabeta , Glynase ) ; glyburide plus metformin ( Glucovance ) ; glimepiride ( Amaryl ) ; repaglinide ( Prandin ) ; netaglinide ( Starlix ) ; glipizide ( Glucotrol , GlibeneseR , MinodiabR ) ; gliclazide ( DiamicronR ) ; tolbutamide ( Orinase , Tolinase ) ; glibornuride ( Glutril ) . Known allergy sulfa specific allergy sulfonylurea drug . Known G6PD enzyme deficiency . Pregnant woman . Women must either postmenopausal ( confirmed LAR ) , permanently sterilize , ≤ 50 year old must negative test pregnancy obtain enrollment . Breastfeeding woman agree ( LAR agree ) stop breast feeding Study Drug infusion 7 day follow end Study Drug infusion . Patients already enrol nonobservationonly stroke study , lifeexpectancy &lt; 3 month relate current stroke , unlikely compliant follow . Patients currently receive investigational drug . Patients peripheral IV line place . Mentally incompetent ( prior qualify stroke ) patient wards state . Patients , opinion investigator , suitable study ( reason document ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>